HH Biotechnology Holdings Company (HHBT) Fair Value & Analysis
Real Estate · US · Market cap $1.4K
HH Biotechnology Holdings Company
HHBT · US
Fair value as of: Aug 18, 2026
From 11 valuation models · updated today
A solid business, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- As a real-estate business, asset- and dividend-based methods carry more weight here than a standard DCF.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 18, 2026.
How to read this chart
60‑month range $0.0001 – $3.80 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Aug 18, 2026.
Analysis
HH Biotechnology Holdings Company (HHBT) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 71/100 (solid quality), in the Real Estate sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, HH Biotechnology Holdings Company generated revenue of $8.0M at a net margin of 36.2%. Revenue grew 10.2% year over year. It earns a return on equity of 9.5%. Fundamentals as of Aug 18, 2026
The share trades about 67% below its 52-week high, currently above its 200-day average. For context, the median of 10 Real Estate peers we cover trades at 15% fair-value upside, at 0%, HHBT screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 11 models by family
Widest divergence: DCF Models ($3.08) versus Asset-Based ($1.34). Highest evidence: Growth DCF (80).
Notify me when HHBT reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 18, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 70 · Market factors (momentum, volatility) 13
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016.
Full company description
HH Biotechnology Holdings Company engages in health and green industries. It focuses on planting and supplying macadamia nuts for use in foods, cooking oils, healthy products, toiletries, and cosmetics. The company was formerly known as Great China International Holdings, Inc. and changed its name to HH Biotechnology Holdings Company in August 2016. HH Biotechnology Holdings Company was incorporated in 1987 and is headquartered in Shenyang, the People's Republic of China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2012 – FY2015 · reported fiscal years
HH Biotechnology Holdings Company reported revenue of $8.0M in FY2015 versus $7.4M in FY2012, a compound +2.8%/yr. Reported net income was $2.5M in FY2015.
Watch HHBT: get an alert when its fair value changes →
Peer Group
Real Estate Services · 530 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Real Estate Services stocks, each showing price versus our Fair Value estimate (as of Aug 18, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Plaza S.A MALLPLAZA | 3,989 CLP | 4,571 CLP | +15% |
| PT Solusi Tunas Pratama Tbk SUPR | 43,850 IDR | 15,049 IDR | -66% |
| Cencosud Shopping S.A CENCOMALLS | 2,412 CLP | 2,976 CLP | +23% |
| PT Sarana Menara Nusantara Tbk. owns and TOWR | 392.00 IDR | 1,012 IDR | +158% |
| PT Metropolitan Kentjana Tbk MKPI | 22,000 IDR | 19,160 IDR | -13% |
| PT Bangun Kosambi Sukses Tbk, CBDK | 3,610 IDR | 3,464 IDR | -4% |
| IRSA Inversiones y Representaciones Sociedad Anónima, IRSA | 2,495 ARS | 2,990 ARS | +20% |
| PT Plaza Indonesia Realty Tbk PLIN | 2,510 IDR | 2,698 IDR | +7% |
| PT MNC Tourism Indonesia Tbk, KPIG | 74.00 IDR | 122.12 IDR | +65% |
| PT Indonesian Paradise Property Tbk INPP | 770.00 IDR | 291.52 IDR | -62% |
Compare HH Biotechnology Holdings Company with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Real Estate stocks →
Frequently asked questions
Is HH Biotechnology Holdings Company (HHBT) overvalued or undervalued?
What is the fair value of HHBT?
What is the quality score of HHBT?
What is the revenue of HH Biotechnology Holdings Company (HHBT)?
What is the net profit margin of HHBT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track HH Biotechnology Holdings Company and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.